• Merck Serono SA, of Geneva, said it is taking its first step into the biosimilar space through a partnership with Dr. Reddy's Laboratories Ltd., of Hyderabad, India. The partnership will focus on co-developing a portfolio of biosimilar cancer compounds, most of which will be monoclonal antibodies. The agreement, based on full R&D cost-sharing, covers co-development, manufacturing and commercialization of the compounds.